RT Journal Article SR Electronic T1 Comparative diagnostic performance of the new chromatographic Affimer®-based rapid antigen detection against SARS-CoV-2 and other standard antigen tests for COVID-19 in a clinical setting JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.18.22269401 DO 10.1101/2022.01.18.22269401 A1 A.I. Gil-Garcia A1 A. Lopez-Lopez A1 J.M. Rubio A1 J.J. Montoya A1 Y. Ouahid A1 A. Madejon A1 P. Castan YR 2022 UL http://medrxiv.org/content/early/2022/01/26/2022.01.18.22269401.abstract AB The availability of accurate and rapid diagnostic tools for COVID-19 is essential for tackling the ongoing pandemic. In this context, researchers in the UK have started testing a new Lateral Flow Device (LFD) based on proprietary Biotinylated anti SARS-CoV-2 S1 Affimer® technology that binds to the SARS-CoV2-S1 protein in anterior nasal swab samples, generating an ultra-sensitive method for detection. This international study aimed to compare its performance against other available antigen-detecting rapid diagnostic tests (Ag-RDTs) in a real-world clinical setting. The study was completed under the frame of Project SENSORNAS RTC-20176501 in collaboration with MiRNAX Biosens Ltd. and Hospital Carlos III, it was documented internally and deposited in agreement to the ISO 13485 norm. All the data obtained are currently under submission and review from the Ethics Committee of Universidad Autonoma de Madrid.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:--- The study was subjected to revision by the Ethics Committee of Universidad Autonoma de Madrid (Arzobispo Morcillo, 4. 28029, Madrid) and the Institutional Review Board of Hospital Carlos III (Sinesio Delgado, 10. 28929, Madrid). --- Decision made, Full ethical approval was given to the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study was completed under the frame of Project SENSORNAS RTC-20176501 in collaboration with MiRNAX Biosens Ltd. and Hospital Carlos III, including a total of 100 samples (50 negatives and 50 positives), each test was documented internally and deposited in agreement to the ISO 13485 norm.